Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib

2Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Nintedanib, a tyrosine kinase inhibitor, is approved for the treatment of idiopathic pulmonary fibrosis. We report a case of left ventricular dysfunction in a patient with idiopathic pulmonary fibrosis treated with nintedanib, which recovered after cessation of nintedanib. Nintedanib may induce left ventricular dysfunction, and early recognition is important since this condition is potentially reversible.

Cite

CITATION STYLE

APA

Imai, R., & Tomishima, Y. (2020). Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib. Respirology Case Reports, 8(2). https://doi.org/10.1002/rcr2.533

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free